BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium
October 29, 2021 15:44 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases...
Global Infection Surveillance Solutions Market is Forecast to Reach $1.03 Billion by 2026, Rising at a CAGR of 15.2%
October 01, 2021 04:58 ET
|
Research and Markets
Dublin, Oct. 01, 2021 (GLOBE NEWSWIRE) -- The "Global Infection Surveillance Solutions Market by Software (Cloud-based), Service (Product Support, Maintenance, Implementation), End-user (Hospitals...
BioAegis Awarded BARDA Contract to Advance Development of Gelsolin, a Novel Host-Directed Human Protein, for Patients with Sepsis and Severe Infection
June 29, 2021 13:58 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
EY Announces Dr. Susan L. Levinson of BioAegis Therapeutics Inc. as an Entrepreneur Of The Year® 2021 New Jersey Award Finalist
June 04, 2021 13:00 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., June 04, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases...
Global Hospital Acquired Disease Testing Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
May 27, 2021 06:58 ET
|
Research and Markets
Dublin, May 27, 2021 (GLOBE NEWSWIRE) -- The "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
Study identifies high-impact postoperative complications in older patients undergoing hip fracture repair
March 23, 2021 12:00 ET
|
Joint Commission
OAKBROOK TERRACE, Ill., March 23, 2021 (GLOBE NEWSWIRE) -- Hip fracture in older patients is common, debilitating and costly.1,2,3 A new study in the April 2021 issue of The Joint Commission Journal...
BioAegis Therapeutics Completes Recruitment for Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
March 15, 2021 11:12 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., March 15, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases based...
NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
November 15, 2020 19:35 ET
|
BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Eagle Hill School First to Use RxAir® UV Light Air Purifiers Campus-Wide to Combat Airborne Viruses
October 13, 2020 08:00 ET
|
Vystar Corp.
RxAir® UV-C Light inactivates 99.9% of airborne viruses, bacteria, mold & fungiTeachers more comfortable teaching in-person with RxAir in useVystar offering discounts to education institutions for...